Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 3:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 113 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Stage 1 Hypertension Clear all
Enrolling by invitation Phase 3 Interventional

A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension

NCT03683186
View directory record Official record
Conditions
PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
Interventions
Ralinepag
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
48
States / cities
Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 38 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Sep 30, 2026, 3:03 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

TEPH: Telaglenastat Efficacy in Pulmonary Hypertension

NCT07223528
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Telaglenastat
Drug
Lead sponsor
Chan, Stephen, MD, PhD
Other
Eligibility
18 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 30, 2026, 3:03 PM EDT
Terminated Phase 2 Interventional Results available

Open-Label Extension Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1)

NCT02736149
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
ubenimex
Drug
Lead sponsor
Eiger BioPharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
26
States / cities
Beverly Hills, California • La Jolla, California • Palo Alto, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Sep 30, 2026, 3:03 PM EDT
Not listed Not applicable Interventional

Evaluation of a Decision Support Tool

NCT02060981
View directory record Official record
Conditions
Medication Adherence, Hypertension, Decision Making, Shared, Patient-Centered Outcomes Research
Interventions
Control, Interview Only, Interview plus decision support tool
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
25 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 18, 2015 · Synced Sep 30, 2026, 3:03 PM EDT
Completed Phase 1Phase 2 Interventional

Phase 1-2 Evaluation of OT-730 Eye Drops in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-Angle Glaucoma

NCT00753168
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
OT-730 ophthalmic solution, timolol maleate ophthalmic solution, OT-730 placebo
Drug
Lead sponsor
Othera Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
5
States / cities
Artesia, California • Roswell, Georgia • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2009 · Synced Sep 30, 2026, 3:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of 7 Days of Grape Seed Extract Supplementation on Cold Pressor Test and Muscle Metaboreflex in Individuals With Elevated and Stage 1 Hypertension

NCT06428890
View directory record Official record
Conditions
Prehypertension
Interventions
Grape Seed Extract, Placebo
Dietary Supplement
Lead sponsor
California Baptist University
Other
Eligibility
18 Years to 30 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Riverside, California
Source: ClinicalTrials.gov public record
Updated May 24, 2024 · Synced Sep 30, 2026, 3:03 PM EDT
Terminated Phase 2 Interventional Results available

Aspirin to Prevent Preeclampsia in Women With Elevated Blood Pressure and Stage 1 Hypertension (ASPPIRE)

NCT04402385
View directory record Official record
Conditions
Pre-Eclampsia, Stage 1 Hypertension, Elevated Blood Pressure
Interventions
Aspirin 81 mg, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Sep 30, 2026, 3:03 PM EDT
Completed Not applicable Interventional Results available

HIRREM for Stage 1 Primary Hypertension

NCT03479697
View directory record Official record
Conditions
Hypertension, Blood Pressure, Cardiovascular Diseases, Cardiovascular Risk Factor, Autonomic Nervous System Imbalance
Interventions
HIRREM, Continued Current Care
Device · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Sep 30, 2026, 3:03 PM EDT
Completed Not applicable Interventional

Effectiveness of Yoga on Ambulatory Blood Pressure in Patients With Pre- and Stage I Hypertension

NCT01542359
View directory record Official record
Conditions
Hypertension
Interventions
Yogic practice, Conventional Exercise
Other
Lead sponsor
Long Island University
Other
Eligibility
21 Years to 74 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jan 10, 2013 · Synced Sep 30, 2026, 3:03 PM EDT
Enrolling by invitation Not applicable Interventional

Advancing Care Coordination Between Cancer and Primary Care Teams for Complex Cancer Survivors

NCT06834204
View directory record Official record
Conditions
Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3), Bladder Cancer, Prostate Cancer (Adenocarcinoma), Endometrial Cancer, Hypertension, Hyperlipidemia (E.G., Hypercholesterolemia), Diabetes Mellitus
Interventions
PC2: Primary Care Connect
Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Sep 30, 2026, 3:03 PM EDT
Completed Phase 2 Interventional Results available

A Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1)

NCT02664558
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
ubenimex, placebo
Drug · Other
Lead sponsor
Eiger BioPharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
28
States / cities
Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Sep 30, 2026, 3:03 PM EDT
Completed Not applicable Interventional

Mindfulness-Based Blood Pressure Reduction (MB-BP) Intervention Development - Stage 1 Single Arm Trial

NCT02702258
View directory record Official record
Conditions
Prehypertension, Hypertension
Interventions
MB-BP
Behavioral
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Sep 30, 2026, 3:03 PM EDT
Completed Phase 2 Interventional

Blueberry Consumption Improves Vascular Function and Lowers Blood Pressure in Postmenopausal Women With Pre- and Stage 1-hypertension

NCT01686282
View directory record Official record
Conditions
Blood Pressure
Interventions
Freeze-dried Blueberry Powder, Placebo
Dietary Supplement
Lead sponsor
Florida State University
Other
Eligibility
45 Years to 65 Years · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Jan 14, 2015 · Synced Sep 30, 2026, 3:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 PK Study to Evaluate the PK of CIN-107 in Subjects With Hepatic Impairment

NCT05961397
View directory record Official record
Conditions
Hypertension
Interventions
baxdrostat
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
5
States / cities
Rialto, California • Miami, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Sep 30, 2026, 3:03 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension

NCT06137742
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
PF-07868489, Placebo for PF-07868489
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
16
States / cities
Anaheim, California • Costa Mesa, California • Orange, California + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Sep 30, 2026, 3:03 PM EDT
Completed Phase 4 Interventional

A Randomized, Double-blind, Placebo Controlled Comparison of Telmisartan Hydrochlorothiazide (HCT) and Valsartan HCT in Hypertension (HTN) Stage I/II Patients

NCT00240448
View directory record Official record
Conditions
Hypertension
Interventions
telmisartan 80 mg/hydrochlorothiazide 25 mg, valsartan 160 mg/hydrochlorothiazide 25 mg, placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
100
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 90 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2013 · Synced Sep 30, 2026, 3:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Relaxation Response Training to Treat Hypertension

NCT01263743
View directory record Official record
Conditions
Hypertension
Interventions
Relaxation Response
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 19, 2016 · Synced Sep 30, 2026, 3:03 PM EDT
Completed Phase 2 Interventional Results available

A Trial to Evaluate the Safety and Efficacy of PS433540 to Treat Hypertension

NCT00522925
View directory record Official record
Conditions
Hypertension
Interventions
PS433540, placebo
Drug
Lead sponsor
Ligand Pharmaceuticals
Industry
Eligibility
30 Years to 80 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
15
States / cities
Tempe, Arizona • Lincoln, California • Long Beach, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2011 · Synced Sep 30, 2026, 3:03 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Dietary Guidelines for Americans-Ultra Processed Study

NCT07252037
View directory record Official record
Conditions
Overweight , Obesity, Class I Obesity
Interventions
Low-processed DGA Diet, Ultra-processed DGA Diet
Other
Lead sponsor
USDA Grand Forks Human Nutrition Research Center
Federal
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Grand Forks, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Sep 30, 2026, 3:03 PM EDT
Completed Not applicable Interventional

Clinical Effectiveness of Boxing Training in Individuals With Elevated Blood Pressure or Stage 1 Hypertension

NCT06413251
View directory record Official record
Conditions
Elevated Blood Pressure, Hypertension
Interventions
Boxing Training, Control flexibility
Other
Lead sponsor
University of Texas, El Paso
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2024 · Synced Sep 30, 2026, 3:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Advancing Understanding of Transportation Options

NCT04141891
View directory record Official record
Conditions
Diabetic Retinopathy, Macular Degeneration, Glaucoma, Retinitis Pigmentosa, Vision Disorders, Acute Coronary Syndrome, Implantable Defibrillator User, Congestive Heart Failure, Hypertrophic Obstructive Cardiomyopathy, Orthostatic Hypotension, Syncope, Presyncope, Narcolepsy, Dementia, Multiple Sclerosis, Parkinson Disease, Brain Injuries, Spinal Cord Injuries, Stroke, Vertigo, Dizziness, Seizures, Substance Use, Insulin Dependent Diabetes Mellitus, Arthritis, Foot--Abnormalities, Chronic Obstructive Pulmonary Disease, Obstructive Sleep Apnea, End Stage Renal Disease, Sleep Apnea, Insomnia, Restless Legs Syndrome
Interventions
Driving Decision Aid, Older Drivers Website
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
529 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
3
States / cities
La Jolla, California • Aurora, Colorado • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 21, 2025 · Synced Sep 30, 2026, 3:03 PM EDT
Recruiting Phase 1Phase 2 Interventional

REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular Hypertension

NCT07675824
View directory record Official record
Conditions
Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Interventions
REGN22530
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Deerfield Beach, Florida
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Sep 30, 2026, 3:03 PM EDT
Completed Phase 2 Interventional Results available

FK506 (Tacrolimus) in Pulmonary Arterial Hypertension

NCT01647945
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Placebo, FK506 level < 2 ng/ml, FK506 level 2-3 ng/ml, FK506 level 3-5 ng/ml
Drug
Lead sponsor
Edda Spiekerkoetter
Other
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2016 · Synced Sep 30, 2026, 3:03 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Topical Insulin for Glaucoma (TING2)

NCT07619482
View directory record Official record
Conditions
Open Angle Glaucoma, Primary Open Angle Glaucoma, Low Tension Glaucoma, Pigmentary Glaucoma, Pseudoexfoliation Glaucoma
Interventions
EYED-002 Low Dose (721 U/mL topical insulin), EYED-002 High Dose (1442 U/mL topical insulin), EYED-002 (highest tolerated dose, 12-month), Vehicle Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 90 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 30, 2026, 3:03 PM EDT